The drug works by activating Kv7, a channel that regulates electrical impulses and neurotransmitter release between neurons. The approach hasn't been validated in bipolar mania. The "lowest risk ...

The PROHEAR Study is a placebo-controlled, randomized, double-blind, split-body trial in which participants receive ACOU085, a Kv7.4 channel activator, in one ear and a placebo in the contralateral ...